Insider Trading in Focus: Nymox Pharmaceutical Corporation $NYMX

success-1093891_1920

Nymox Pharmaceutical Corporation (NYMX) insider have most recently took part in a trading activity. On Jun 28, 2017 Robinson James George, Director bought 8,500 shares having total worth of $34,765 at the price of $4.09 per share, following the transaction a total of 3,095,600 shares owned by Robinson James George. Before this latest buy, Robinson James George purchased NYMX at 10 other times during the past twelve months, for a total investment of $773,325 at an average of $3.49 per share.

The stock has experienced a total of 3 insider trades in the past three months. These trades include 3 buy trades. Furthermore, over the past 12 months , the stock was traded 10 times by insiders. an employee of the company was the buyer in 10 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 3 0 19.88%
12 Month 10 0 90.7%

Shares of Nymox Pharmaceutical Corporation (NYMX) traded down 1.68% on Jun 28, 2017, hitting $4.1. 161,018 shares of the company’s stock traded hands. Nymox Pharmaceutical Corporation has a 52 week low of $1.85 and a 52 week high of $4.99. The company’s market cap is $154 million.

Nymox Pharmaceutical Corporation (NYMX) last announced its earnings results on May 16, 2017. The company reported -0.06 earnings per share (EPS) for the quarter. The company had revenue of $0 million for the quarter

2017-05-16 2015-12-31 2015-08-24 2015-05-15 2015-03-31 2014-11-14 2014-08-11 2014-05-15 2012-08-14
earnings per share -0.06 -0.26 -0.14 0.04 -0.02 -0.02 -0.02 -0.07 -0.05
Revenue(M) 0.08 0.05 0.06 2.58 0.07 0.08 0.1 0.08 0

Nymox Pharmaceutical Corporation was incorporated under the Canada Business Corporations Act in May 1995. The Company operates in one reportable segment – the research and development of products for the aging population. The Company conducts R&D and manufacturing for NicAlert and TobacAlert. It is a biopharmaceutical Corporation with three proprietary products on the market, and significant R&D pipeline of products in development. The Company has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. It is developing new treatments for bacterial infections in humans. NicAlert received clearance from the U.S. FDA and is also certified with a CE Mark in Europe. TobacAlert is the first test of its kind to measure second and third hand smoke exposure in individuals. The Company has developed AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer’s disease. The Company is developing NX-1207, a novel treatment for benign prostatic hyperplasia which is in Phase 3 trials in the U.S. An open-label U.S. re-injection safety study of NX-1207 for BPH was started in July of 2011 and reached completion of its primary endpoint assessment in January 2013. The company is developing new antibacterial agents for the treatment of bacterial infections in humans, including a treatment for E-coli O157:H7 bacterial contamination in meat and other food and drink products. The Company is subject to continuing potential product liability risks.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.